ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1506

Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort

Chrisitine Galant1, Laurent Meric de Bellefon2, Bernard R. Lauwerys3, Tatiana Sokolova2, Maria Stoenoiu2, Valérie Badot4, Adrien Nzeusseu Toukap3, Frédéric A. Houssiau5 and Patrick Durez2, 1Pathology, Pathology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 2Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 3Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 4Internal Medicine, Internal Medicine - Centre Hospitalier Universitaire Brugmann, Brussels, Belgium, 5Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis and biomarkers

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The development of ultrasound (US) guided synovial biopsy will enable synovial tissue collection from small joints and will facilitate histopathological studies, thus improving the understanding of early rheumatoid arthritis (ERA). The CAP48 cohort is an original multicentre prospective observational study of ERA patients (pts) up to 50 years old supported by a charity program of the Belgian French speaking radio-television (RTBF). The objectives of this cohort are to observe if a tight control favours remission at 6 months and to define synovial markers for disease severity and response to therapy.

Methods:

ERA pts fulfilling the ACR/EULAR 2010 criteria and naive to DMARDs therapy were recruited. Synovial biopsies before treatment were obtained using an US guided needle biopsy (US-NB) of the small joints or miniarthroscopy of the knee and used for blinded tissue pathotype description. ERA disease activity measures including DAS28CRP were evaluated every 3 months and treatment was adapted by the treating physician. Tissues were assessed for quality. Pts were classified according 3 types of synovial histopathology findings: pts whose synovial tissue showing mostly lymphoid (CD3+ and CD20+) infiltrates, myeloid (CD68+) infiltrates and a group with low inflammation, combined or not with a fibroid aspect of the stroma, clustered, respectively in Lymphoid, Myeloid and Pauci-Immune groups.

Results:

A synovial biopsy was performed in 37 pts. Baseline characteristics of the cohort and different histologic pattern groups are summarized in Table.

All patients

n=37

‘Lymphoid’

group

n=18

‘Myeloid’

group

n=6

‘Pauci-Immune’

group

n=13

Age

mean (SD)

34.6 (± 11.6)

31.2 (± 10.9)

38.4 (± 11.7)

37.7 (± 11.9)

Gender

30F/7M

14F/4M

5F/1M

11F/2M

ACPA %

37.8% (n= 14)

22.2% (n=4)

0% (n=6)

76.9% (n=10)

RF %

48.6% (n=18)

38.9% (n=7)

16.7% (n=1)

76.9% (n=10)

Erosion %

32.4% (n=12)

27.8% (n=5)

33.3% (n=2)

38.4% (n=5)

Baseline DAS28CRP

4.60 (± 1.37)

4.46 (± 1.42)

5.24 (± 1.52)

4.50 (± 1.26)

6 Month DAS28CRP

2.68 (± 1.13)

2.19 (± 0.89)

*

2.83 (± 1.44)

3.15 (± 1.13)

* p=0.023

ACPA negative pts were classified in the Myeloid (100%) or in Lymphoid (77.8%) groups compared to a majority of the ACPA positive pts (76.9%) in the Pauci-Immune group. Since the myeloid pattern can be associated with a lymphoid infiltration, it raised a question on the relevance to maintain a distinct subgroup. The Pauci-Immune RA group showed lower DAS28-CRP response than the other groups.

Conclusion:

Synovial tissue analysis could provide a step change towards personalized medicine in daily clinical practice for disease stratification and treatment selection of ERA. In the CAP48 cohort, a high number of these young and ERA pts achieved remission at 6 months but a lower response was observed in the Pauci-Immune group. Further analyses are ongoing to define individual synovial markers of severity and response.


Disclosure: C. Galant, None; L. Meric de Bellefon, None; B. R. Lauwerys, None; T. Sokolova, None; M. Stoenoiu, None; V. Badot, None; A. Nzeusseu Toukap, None; F. A. Houssiau, None; P. Durez, None.

To cite this abstract in AMA style:

Galant C, Meric de Bellefon L, Lauwerys BR, Sokolova T, Stoenoiu M, Badot V, Nzeusseu Toukap A, Houssiau FA, Durez P. Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/synovial-tissue-histopathology-findings-in-early-ra-is-it-usefull-analysis-of-the-belgian-cap48-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-tissue-histopathology-findings-in-early-ra-is-it-usefull-analysis-of-the-belgian-cap48-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology